search
Back to results

DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers (DO IT)

Primary Purpose

Respiratory Tract Infections, Asthma, Avitaminosis

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Vitamin D - Cholecalciferol 400 IU
Vitamin D3 - Cholecalciferol 2000 IU
Sponsored by
The Hospital for Sick Children
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Respiratory Tract Infections focused on measuring Vitamin D, Randomized Controlled Trial, Child, Preschool, Dietary Supplements, Respiratory Tract Infections, Asthma

Eligibility Criteria

1 Year - 5 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy children by parental report
  2. Have reached their 1st birthday but not past their 6th birthday
  3. Present to a TARGet Kids! practice for routine primary healthcare prior to viral season (September through November)
  4. Parents provide informed consent to participate.

Exclusion Criteria:

  1. Children with gestational age < 32 weeks
  2. Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection
  3. Children with a sibling participating in the study to reduce clustering effects.

Sites / Locations

  • St. Michael's Hospital
  • Hospital for Sick Children

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

2000 IU per day vitamin D

400 IU per day vitamin D

Arm Description

Outcomes

Primary Outcome Measures

Number of Laboratory confirmed upper respiratory tract infections
Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Reverse transcriptase polymerase chain reaction will be performed on each sample. Samples will be tested for 18 common respiratory viruses using the ID-TagTM RVP assay using the Luminex xMAPTM system.

Secondary Outcome Measures

Number of parent reported upper respiratory tract infections
Parental reported URTI symptoms will be defined as two or more of fever, cough, runny nose, sore throat, headache, vomiting, feels unwell, muscle aches, ear ache or infection, poor appetite, not sleeping well, cranky/fussy, low energy or crying more than usual from a validated parent completed symptom checklist.
Number of Asthma exacerbations
Asthma exacerbation will be defined as a wheezing episode in children with asthma as obtained from parent completed symptom checklist based on the International Study of Asthma and Allergies in Childhood (ISAAC).
Serum vitamin D level
Blood for serum levels will be drawn by trained pediatric phlebotomists from for determination of 25-hydroxyvitamin D. Total 25-hydroxyvitamin D will be measured from serum samples using a competitive two-step chemiluminescence assay.
Direct and indirect economic costs associated with upper respiratory tract infections
Cost-consequence and cost-effectiveness analyses will be conducted using data from this clinical trial. A societal perspective will be employed as both direct health service utilization costs as well as indirect costs to families from URTI will be calculated for the 400 IU per day versus 2000 IU per day groups.

Full Information

First Posted
August 16, 2011
Last Updated
June 11, 2019
Sponsor
The Hospital for Sick Children
Collaborators
Mount Sinai Hospital, Canada, Unity Health Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT01419262
Brief Title
DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers
Acronym
DO IT
Official Title
DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Hospital for Sick Children
Collaborators
Mount Sinai Hospital, Canada, Unity Health Toronto

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Vitamin D can be made in the skin by exposure to sunlight and can be found in certain foods. Vitamin D levels are alarmingly low in many North American children. Several health issues have been linked with low vitamin D. These include colds caused by viruses and asthma attacks. However, no study has determined whether vitamin D supplementation can reduce the risk of these conditions in young children where they are most common and most severe. The goals of this study are to determine whether wintertime high dose vitamin D supplementation of preschoolers can prevent colds and asthma attacks. The investigators also aim to work out how much money would be saved by the health care system and society if preschoolers were routinely supplemented with Vitamin D during the winter. The investigators believe that preschoolers receiving 'high dose' vitamin D supplementation during the wintertime will be less likely to have colds, asthma attacks, and low vitamin D levels and will be less likely to use the medical system and keep their parents away from work.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Tract Infections, Asthma, Avitaminosis
Keywords
Vitamin D, Randomized Controlled Trial, Child, Preschool, Dietary Supplements, Respiratory Tract Infections, Asthma

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
703 (Actual)

8. Arms, Groups, and Interventions

Arm Title
2000 IU per day vitamin D
Arm Type
Experimental
Arm Title
400 IU per day vitamin D
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Vitamin D - Cholecalciferol 400 IU
Other Intervention Name(s)
Baby Ddrops, Health Canada NPN #80001869
Intervention Description
One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Intervention Type
Drug
Intervention Name(s)
Vitamin D3 - Cholecalciferol 2000 IU
Other Intervention Name(s)
Ddrops 2000 IU
Intervention Description
One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Primary Outcome Measure Information:
Title
Number of Laboratory confirmed upper respiratory tract infections
Description
Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Reverse transcriptase polymerase chain reaction will be performed on each sample. Samples will be tested for 18 common respiratory viruses using the ID-TagTM RVP assay using the Luminex xMAPTM system.
Time Frame
Up to 8 months
Secondary Outcome Measure Information:
Title
Number of parent reported upper respiratory tract infections
Description
Parental reported URTI symptoms will be defined as two or more of fever, cough, runny nose, sore throat, headache, vomiting, feels unwell, muscle aches, ear ache or infection, poor appetite, not sleeping well, cranky/fussy, low energy or crying more than usual from a validated parent completed symptom checklist.
Time Frame
Up to 8 months
Title
Number of Asthma exacerbations
Description
Asthma exacerbation will be defined as a wheezing episode in children with asthma as obtained from parent completed symptom checklist based on the International Study of Asthma and Allergies in Childhood (ISAAC).
Time Frame
Up to 8 months
Title
Serum vitamin D level
Description
Blood for serum levels will be drawn by trained pediatric phlebotomists from for determination of 25-hydroxyvitamin D. Total 25-hydroxyvitamin D will be measured from serum samples using a competitive two-step chemiluminescence assay.
Time Frame
5-8months
Title
Direct and indirect economic costs associated with upper respiratory tract infections
Description
Cost-consequence and cost-effectiveness analyses will be conducted using data from this clinical trial. A societal perspective will be employed as both direct health service utilization costs as well as indirect costs to families from URTI will be calculated for the 400 IU per day versus 2000 IU per day groups.
Time Frame
16 months
Other Pre-specified Outcome Measures:
Title
Body Mass index z-score
Description
Weight and height will be measured at both study baseline and follow-up by trained research assistants. BMI will be determined by dividing the children's measured weight (kg) by height (m2). The BMI z-score [zBMI] will be determined using the World Health Organization Growth standards, standardized for age and sex.
Time Frame
Up to 8 months
Title
Waist circumference z-score
Description
Waist circumference will be measured at both study baseline and follow-up by trained research assistants. Waist circumference will be measured at the mid-axillary line above the right iliac crest. Waist circumference z-score will be calculated internally within the entire TARGet Kids! study cohort.
Time Frame
Up to 8 months
Title
Serum Lipids
Description
Blood for serum levels will be drawn by trained pediatric phlebotomists from for determination of total cholesterol, low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol and non-HDL cholesterol.
Time Frame
Up to 8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy children by parental report Have reached their 1st birthday but not past their 6th birthday Present to a TARGet Kids! practice for routine primary healthcare prior to viral season (September through November) Parents provide informed consent to participate. Exclusion Criteria: Children with gestational age < 32 weeks Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection Children with a sibling participating in the study to reduce clustering effects.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathon L Maguire, MD, MSc
Organizational Affiliation
St. Michael's Hospital, Toronto, Ontario, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
Hospital for Sick Children
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
33305842
Citation
Huey SL, Acharya N, Silver A, Sheni R, Yu EA, Pena-Rosas JP, Mehta S. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD012875. doi: 10.1002/14651858.CD012875.pub2.
Results Reference
derived
PubMed Identifier
28719693
Citation
Aglipay M, Birken CS, Parkin PC, Loeb MB, Thorpe K, Chen Y, Laupacis A, Mamdani M, Macarthur C, Hoch JS, Mazzulli T, Maguire JL; TARGet Kids! Collaboration. Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA. 2017 Jul 18;318(3):245-254. doi: 10.1001/jama.2017.8708.
Results Reference
derived

Learn more about this trial

DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers

We'll reach out to this number within 24 hrs